Maurel J, et al. - In this multi-institutional phase 2 trial, researchers assessed the outcomes after neoadjuvant therapy (NAT) in patients with confirmed resectable pancreatic adenocarcinoma (PDAC). They evaluated tumor regression grade (TRG) and resection margin status among patients treated with three cycles of GEM (1,000 mg/m²/week) plus daily erlotinib (ERL; 100 mg/day), followed by 5 weeks of therapy with GEM (300 mg/m2/week), ERL 100 mg/day and concomitant radiotherapy (45 Gy) in patients without progressive disease on re-staging. Mild gastrointestinal disorders were reported as the main adverse effects of NAT. Among the resected patients, the resectability rate was 76%, with a R0 rate of 63.1%. The estimated median overall survival (OS) and disease-free survival were 23.8 and 12.8 months, respectively. A better median OS was seen among R0 resection patients vs patients with R1 resection or those not resected. Findings confirmed promising oncologic results with NAT for patients with resectable PDAC.